Latest Conference Articles

This video includes a discussion of different procedures designed to help treat patients with hidradenitis suppurativa (HS) and atopic dermatitis.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

Jonathan Barratt, MD, PhD, offers perspective on how the 100-week data from ERA 25 inform the potential of zigakibart.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

Check out these 7 late-breaking abstracts to watch at the upcoming SLEEP 2025 meeting.

During his New Wave Dermatology interview, Naveed Sami, MD, spoke about additional takeaways from his session on the cutaneous effects of immunotherapies.

In this interview at the New Wave Dermatology meeting, Naveed Sami, MD, highlights some of the notable takeaways from his talk on the impacts of immunotherapies.

This interview from the 2025 New Wave Dermatology Conference features DiRuggiero discussing challenging psoriasis cases and tips for healthcare providers.

This Q&A interview highlights reductions observed in the use of rilzabrutinib for asthma symptom relief in a recent phase 2 study.

During her ATS interview, Lisa Wood, PhD, spoke about economic and geographic disparities and their connection to diet and related respiratory health outcomes.

This ATS interview features Lisa Wood, PhD, discussing recent findings related to childhood dietary intake and its connection to respiratory health.

Bose explains her research on vaping among millennial adults who may be at peak lung health, describing the diverse landscape of vaping devices and products.

View conference highlights from HCPLive’s coverage of the American Thoracic Society (ATS) International Conference 2025.

In this interview, nerandomilast’s safety profile in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is highlighted.

Attaway reviews data demonstrating the potential benefit of a subspecialty clinic for overcoming current diagnostic and treatment-related challenges for sarcopenia in COPD.

This interview highlights phase 3 trial data on nerandomilast’s use in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Prevot describes her research exploring the relationship between OSA severity and abdominal obesity metrics as well as changes in both metrics following CPAP.

These data from ATS 2025 highlight patients’ real-world outcomes related to treatment of their chronic obstructive pulmonary disease (COPD) with dupilumab.

The analysis of pooled data from BOREAS and NOTUS highlight dupilumab’s sustained impact on lung function in patients with COPD and type 2 inflammation.

In this interview, Chalmers highlights the implications of his team’s subgroup analysis findings in the ASPEN trial, as well as unmet needs for non-cystic fibrosis bronchiectasis.

Findings from a post hoc analysis of the phase 3 DIRECTION study highlight tezepelumab’s consistent benefit on asthma exacerbations across trigger categories.

Trief and MD candidate Justin Cheong physically peeled the Haab’s striae from a patient’s eye, allowing for better adherence and maintenance of the DSEK graft.

At ATS 2025, these data highlight a potential connection between asthma development and prenatal exposure to microplastics and other forms of pollution.

Murphy discusses innovative surgical techniques for managing glaucoma and cataracts, emphasizing minimally invasive approaches and the future of ophthalmology.

This interview highlights the subgroup analysis findings of the ASPEN trial, specifically on brensocatib for non-cystic fibrosis bronchiectasis.

This special episode of Lungcast features Harold P. Wimmer, CEO of the ALA, and Francesca Polverino, MD, PhD, an ALA spokesperson.

Gerard Criner, MD, reviews findings from a secondary analysis of the phase 3 MATINEE trial of mepolizumab and looks ahead to the potential significance of the drug, if approved.